Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Instruments & Supplies

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Revenue projections:

Revenue projections for BDX
Revenue projections for BDX

BDX is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.

Financial Ratios:

currentRatio 1.049000
forwardPE 11.501974
debtToEquity 77.284000
earningsGrowth 0.286000
revenueGrowth 0.016000
grossMargins 0.467840
operatingMargins 0.133470
trailingEps 6.130000
forwardEps 13.503770

Becton, Dickinson and Company's current ratio of 1.049 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, Becton, Dickinson and Company can comfortably cover its liabilities, reflecting a strong financial outlook.
Becton, Dickinson and Company's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.
Becton, Dickinson and Company's forward EPS exceeds its trailing EPS, indicating that the company is projected to be more profitable in the current financial year compared to the previous one. This suggests positive growth and improved earnings, signaling an optimistic outlook for Becton, Dickinson and Company's financial performance.

Price projections:

Price projections for BDX
Price projections for BDX

The gradual downward revision of BDX's price projections signals decreasing confidence in the company's future performance. Analysts are adjusting their expectations, reflecting uncertainty about BDX's growth potential.

Insider Transactions:

Insider Transactions for BDX
Insider Transactions for BDX


BDX had 20 sell transactions, while the market price was at 158.13710098266603 per share.1 purchases of BDX were executed, with market price of 151.3364715576172.The higher volume of sells at BDX's current price levels could indicate a potential decline. If this selling trend persists, the stock might continue to fall as investor confidence wanes, leading to more downward pressure.

Recommendation changes over time:

Recommendations trend for BDX
Recommendations trend for BDX


Becton, Dickinson and Company has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view Becton, Dickinson and Company as a stable option to park their money and potentially benefit from the company's continued growth and profitability.